Notes
incremental cost-effectiveness ratios
2010/2011 values
Reference
Das R, et al. Economic Evaluation of Fulvestrant 500 mg Versus Generic Nonsteroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer in the United Kingdom. Clinical Therapeutics : 28 Feb 2013. Available from: URL: http://dx.doi.org/10.1016/j.clinthera.2013.01.011
Rights and permissions
About this article
Cite this article
Fulvestrant cost effective for advanced breast cancer?. PharmacoEcon Outcomes News 674, 6 (2013). https://doi.org/10.1007/s40274-013-0242-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0242-8